JBJ.-D. Bouaziz

J.-D. Bouaziz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


J.-D. Bouaziz has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • A. Marie-Cardine

    INSERM U976, Skin Research Centre, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475 Paris, France

    1 shared publication
  • Armand Bensussan

    Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, Paris, France

    1 shared publication
  • M. Bagot

    INSERM U976, Skin Research Centre, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475 Paris, France

    1 shared publication
  • N. Remtoula

    INSERM U976, Skin Research Centre, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475 Paris, France

    1 shared publication

Latest Publications

  • Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome

    by J.-D. Bouaziz, N. Remtoula, A. Bensussan, A. Marie-Cardine, M. Bagot

    Background CD158k/KIR3DL2 is a specific marker for Sézary cells which can be used to diagnose Sézary syndrome (SS) in erythrodermic patients with abnormal circulating T cells. Objectives To evaluate the suitability of CD158k/KIR3DL2 for detecting and evaluating blood tumour load during the follow up of patients with SS. Methods The absolute CD3+ CD158k+ lymphocyte count was compared with the absolute count of cytomorphological Sézary cells and was correlated with clinical flares in a cohort of patients with SS. Twenty‐five patients were included in the study and 48 blood samples were analysed. Results The absolute count of CD3+ CD158k+ cells strongly correlated with the absolute count of atypical circulating cells (r = 0·97, P < 10−15). The CD3+ CD158k+ lymphocyte cell count was in eight cases more sensitive than cytomorphology for detecting atypical circulating cells especially for small‐sized tumour cells. The tumour burden evaluated by CD3+ CD158k+ immunostaining was significantly associated with clinical flare (P < 10−4). Conclusions CD3+ CD158k+ phenotyping is a reliable and objective test to monitor the blood tumour burden in patients with SS under systemic therapy.